about
Antibodies specifically targeting a locally misfolded region of tumor associated EGFRExpression of the adaptor protein Tks5 in human cancer: prognostic potential.Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodellingInhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burdenAntitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib.Single live cell TGF-β signalling imaging: breast cancer cell motility and migration is driven by sub-populations of cells with dynamic TGF-β-Smad3 activity.A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer.The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells.Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burdenTransforming growth factor-beta (TGF-beta) and brain tumours.Defining the essential function of FBP/KSRP proteins: Drosophila Psi interacts with the mediator complex to modulate MYC transcription and tissue growthTargeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden.The role of Stat3 in glioblastoma multiforme.Glycogen synthase kinase-3β (GSK-3β) and its dysregulation in glioblastoma multiforme.The role of STAT3 signaling in mediating tumor resistance to cancer therapy.Mouse models of glioma.Using bioluminescence imaging in glioma research.MicroRNA as potential biomarkers in Glioblastoma.Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib.SPSB1, a Novel Negative Regulator of the Transforming Growth Factor-β Signaling Pathway Targeting the Type II Receptor.miRNA expression profiling of cerebrospinal fluid in patients with aneurysmal subarachnoid hemorrhage.Betaglycan blocks metastatic behaviors in human granulosa cell tumors by suppressing NFκB-mediated induction of MMP2.The emergent role of exosomes in glioma.Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics.Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically.Dynamin II function is required for EGF-mediated Stat3 activation but not Erk1/2 phosphorylation.The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR.Enhancement of invadopodia activity in glioma cells by sublethal doses of irradiation and temozolomide.Effects of EphB4 receptor expression on colorectal cancer cells, tumor growth, vascularization and composition.A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker.Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer.Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-β signallingInhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved DrugsPaclitaxel-Loaded Self-Assembled Lipid Nanoparticles as Targeted Drug Delivery Systems for the Treatment of Aggressive Ovarian CancerPonatinib: a novel multi-tyrosine kinase inhibitor against human malignanciesPaclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer
P50
Q27654155-F91381FC-ED20-43DA-8BBE-4D08A9E79045Q30009380-A4F09F1C-7443-43F2-B19A-1533EB62198EQ33559947-5805220A-CF05-429E-8656-47298079C793Q33628532-17D5834D-819A-40BA-A393-A0093BDC6161Q34792693-D52E4619-CE21-4A47-9CD2-3DA2AFE52A2AQ35009672-88FE6BE5-4B15-4101-BC7F-976B036F6BFDQ35129209-47527015-740C-47C6-A928-27D56F872856Q35936614-F3701396-7F62-45D0-9AE2-29D2ACAFE86BQ36070842-73A214CF-9CE5-4127-9341-6D51CE601260Q36356318-4B0F6D83-C9F7-4068-954A-068DF49D975DQ36891437-33ED16B7-2AD8-430D-8A3C-DBB4BA36039FQ37190193-B44F56A9-A157-41DE-925E-0DAF2F4916ACQ37264327-04FA1989-5E87-425B-BE21-C19C9D581532Q37705457-30404159-727E-434B-BCBB-EAB68A81692BQ38108025-10E65218-4B7D-4903-AA41-AAB953DC1F79Q38114602-A8CE06DD-AD55-43EE-983C-3862ADC17311Q38269722-26B258DA-132D-4EF6-92D8-EFD5CA07F149Q38362445-0E649E26-0B45-42CB-98B4-4B9E28CF1C19Q38393683-8B3CE9C1-45AB-40A1-AFF1-B0FFDD59E0B4Q38590626-D82E17AA-415D-4C1B-B395-4A7AE60A89D5Q38776733-8D0BA5CA-8FC8-47AB-AEF4-9E88B1C2107CQ38868773-43180C02-37EB-41DD-A651-8CC3021CBCEDQ38873944-DEAB1910-6F40-49D3-882F-CCE628D20C1DQ38965493-EA9AB5C2-2D16-4EE3-9494-8AE8E980C6C4Q38988293-A02F3E17-0579-4374-845A-FCFED72EBA7CQ39022069-D593865B-C565-48B3-97F0-96383E2292A9Q39088870-87323BAD-0461-4D8C-899F-D133244681EEQ39109989-BDFAB2C8-89AE-451E-9E45-4D71AE5C808FQ39350866-81896052-D1A8-4B7B-B3D2-9F5B16BB0A8DQ40541045-A9038398-F2BC-4523-A555-4393F5BE3390Q47392190-5A3D23DC-2E7E-4322-BB51-E6956A7988F7Q48168240-D0C7B7C8-E03E-4A6C-ACF1-0617A98AC199Q50000797-FFA4E3CE-9625-4445-9436-0E82E20433FFQ54114902-3AD17B78-E019-478C-AFB3-5CCD38FA697BQ55471079-CD828B79-8D8A-4677-B16C-8FCBC834B123Q57269883-3633076C-F920-4264-9940-BB227CEBD4B4Q58214998-B7A068EA-3D86-42DB-9522-6B2AF3AEA7B9Q60143592-EA56A45E-35F4-41C5-8CDB-8CE241296664Q61813690-9D0A6545-4FA0-4D7F-8245-68ED2F91DC43Q64244088-EC432658-9032-475E-A1A9-F015456FA04B
P50
description
researcher ORCID ID = 0000-0002-3020-4245
@en
name
Rodney B Luwor
@ast
Rodney B Luwor
@en
Rodney B Luwor
@es
Rodney B Luwor
@nl
type
label
Rodney B Luwor
@ast
Rodney B Luwor
@en
Rodney B Luwor
@es
Rodney B Luwor
@nl
prefLabel
Rodney B Luwor
@ast
Rodney B Luwor
@en
Rodney B Luwor
@es
Rodney B Luwor
@nl
P1153
6506316260
P21
P31
P496
0000-0002-3020-4245